Corcept Therapeutics Company Profile

14:35 EST 17th November 2017 | BioPortfolio

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States each year and for which there are no FDA - approved treatments. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. In August 2006 we announced negative top line results of one of our three Phase 3 studies. We expect to report the results the second study in September and the third in late 2006 or early 2007. Our program has been granted "fast track" status by the FDA. We have also initiated a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine.


149 Commonwealth Drive
Menlo Park
United States of America


Phone: (650) 327-3270
Fax: (650) 327-3218

News Articles [516 Associated News Articles listed on BioPortfolio]

Opportunistic Corcept Drop - Rumors, Lies, and Thoughts

Corcept Therapeutics (CORT) experienced a precipitous drop on heavy volume today. Apparently the tracking on Korlym sales went awry as Corcept changed pharmacy services. We wrote about that "lovely ev...

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2017 Results - Earnings Call Transcript

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2017 Results - Earnings Call Transcript

Corcept Therapeutics Inc. To Announce Second Quarter Financial Results, Provide Corporate Update And Host Conference Call

  Life Sciences Jobs   ...

Corcept Therapeutics Inc. Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance And Provides Corporate Update

  Life Sciences Jobs   ...

Corcept Therapeutics Inc CORT Financial and Strategic SWOT Analysis Review [Report Updated: 22062017] Prices from USD $125

Corcept Therapeutics Inc CORT Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...

Dohmen Sues Corcept, Corcept Sues Dohmen, While Jim Cramer High-Fives CORT

Corcept Therapeutics (CORT) terminated its agreement with its distributor, Dohmen Life Sciences, for Korlym to treat Cushing’s Syndrome. On August 7, 2017, Dohmen filed a complaint in the Court of C...

Early Draft - Corcept Mouse Studies - Combination Therapy - CORT125134 & CORT125281 + Checkpoint Inhibitors

While I usually don't release unfinished drafts to the public, I promised a sneak peek to the Investor Village community. This draft will be extended and finished over the next day. Come back and see ...

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1168 Associated Companies listed on BioPortfolio]

Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is curren...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Corcept Therapeutics" on BioPortfolio

We have published hundreds of Corcept Therapeutics news stories on BioPortfolio along with dozens of Corcept Therapeutics Clinical Trials and PubMed Articles about Corcept Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Corcept Therapeutics Companies in our database. You can also find out about relevant Corcept Therapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...

Corporate Database Quicklinks

Searches Linking to this Company Record